ReviewRheumatology (Oxford, England)2022
A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition.
Review in Rheumatology (Oxford, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Pooled it
- Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.Annals of the rheumatic diseases · 2022Trial
- Combining Guselkumab with Upadacitinib Is Safe and Effective in the Treatment of Medically Complex Inflammatory Bowel Disease.Digestive diseases and sciences · 2026Article
- Ginsenoside Rk3 modulates glutamine metabolism and inhibits Th17 cell differentiation via gut microbiota regulation to ameliorate psoriasis.Journal of natural medicines · 2026Article
- Efficacy and safety of tofacitinib in ankylosing spondylitis patients: a systematic review and meta-analysis.Clinics (Sao Paulo, Brazil) · 2026Review
- Diagnostic and therapeutic challenges in concomitant axial spondyloarthritis and rheumatoid arthritis: a case-based review.Rheumatology international · 2026Review
- Comparative treatment persistence of upadacitinib vs. tofacitinib in psoriatic arthritis: a multicenter observational study from the BIRRA cohort.Frontiers in medicine · 2026Article
- Real-World Effectiveness and Safety of Upadacitinib in Tumor Necrosis FactorInhibitor Refractory Axial Spondyloarthritis: 52-Week Outcomes from a Single-Center Cohort.Archives of rheumatology · 2025Article
- Paradoxical Activation of Entheseal Myeloid Cells by JAK1 and Tyk2 Inhibitors via Interleukin-10 Antagonism.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- Case Report: The combination of upadacitinib and adalimumab in the treatment of refractory ankylosing spondylitis.Frontiers in immunology · 2025Article
- Treg cell plasticity as a driver of inflammation in spondyloarthritis and psoriasis.Frontiers in immunology · 2025Review
- Upadacitinib for the treatment of radiographic axial spondyloarthritis - case series and review of the literature.Drugs in context · 2025Article
- Medicinal chemistry perspective of JAK inhibitors: synthesis, biological profile, selectivity, and structure activity relationship.Molecular diversity · 2024Review
- Successful treatment of Crohn's disease-related peripheral spondyloarthritis with upadacitinib: two case reports and case-based review.Rheumatology international · 2024Review
- TNFα Inhibitors Versus Newer Therapies in Spondyloarthritis: Where do we Stand Today?Mediterranean journal of rheumatology · 2024Review
- Extracellular Vesicles Derived from Ligament Tissue Transport Interleukin-17A to Mediate Ligament-To-Bone Crosstalk in Ankylosing Spondylitis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Male Fertility in Spondyloarthritis: from Clinical Issues to Cytokines Milieu. A Narrative Review.Current rheumatology reports · 2024Review
- [Is JAK inhibition an option in the treatment of interstitial lung disease in rheumatoid arthritis?]Zeitschrift fur Rheumatologie · 2024Article
- High-Resolution Structure of RNA G-Quadruplex Containing Unique Structural Motifs Originating from the 5'-UTR of Human Tyrosine Kinase 2 (TYK2).ACS omega · 2024Article
- Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases.Rheumatology (Oxford, England) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spondyloarthritis (SpA) comprises a group of chronic inflammatory diseases with overlapping clinical, genetic and pathophysiological features including back pain, peripheral arthritis, psoriasis, enthesitis and dactylitis. Several cytokines are involved in the pathogenesis of SpA, variously contributing to each clinical manifestation. Many SpA-associated cytokines, including IL-23, IL-17, IL-6, type I/II interferon and tumour necrosis factor signal directly or indirectly via the Janus kinase (JAK)-signal transducer and activator of transcription pathway. JAK signalling also regulates development and maturation of cells of the innate and adaptive immune systems. Accordingly, disruption of this signalling pathway by small molecule oral JAK inhibitors can inhibit signalling implicated in SpA pathogenesis. Herein we discuss the role of JAK signalling in the pathogenesis of SpA and summarize the safety and efficacy of JAK inhibition by reference to relevant SpA clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.